S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide-Reference-Cited by-同舟云学术

S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide

Published:2016-04-25 Issue:23 Volume:7 Page:34630-34642
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Stewart Rachel L.¹²,Carpenter Brittany L.¹³,West Dava S.²,Knifley Teresa¹,Liu Lili⁴,Wang Chi¹⁵,Weiss Heidi L.¹⁵,Gal Tamas S.¹⁶,Durbin Eric B.¹⁶,Arnold Susanne M.¹,O’Connor Kathleen L.¹³,Chen Min¹⁷

Affiliation:

1. Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA

2. Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40506, USA

3. Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY 40506, USA

4. Department of Toxicology, Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, 510300, PR China

5. Department of Biostatistics, University of Kentucky, Lexington, KY 40506, USA

6. Division of Biomedical Informatics, University of Kentucky, Lexington, KY 40506, USA

7. Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40506, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer;Cancer Drug Resistance;2024-09-10

2. S100 Proteins in Cancer;Advances in Clinical Medicine;2024

3. Chemoresistance Mechanisms in Non-Small Cell Lung Cancer—Opportunities for Drug Repurposing;Applied Biochemistry and Biotechnology;2023-09-18

4. Repurposing Niclosamide as a Novel Anti-SARS-CoV-2 Drug by Restricting Entry Protein CD147;Biomedicines;2023-07-18

5. S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8⁺ T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma;Advanced Science;2023-07-06